Only one serious adverse event (pancreatitis) possibly related to GLP-1 agonists, specifically lixisenatide, was observed in one of these studies.8The adverse effects found may limit the acceptance and adherence to treatment, compromising the clinical usefulness of these agents in the daily practice. This evidence concerns the gene GLP1R and pancreatitis.